Esperion (ESPR) announced that HLS Therapeutics (HLTRF) has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks another important milestone in our global strategy to expand access to bempedoic acid products for patients who urgently need better options to manage their LDL-C and reduce cardiovascular risk. We remain deeply committed to delivering innovative therapies that address unmet medical needs and improve outcomes for patients around the world,” said Sheldon Koenig, President and CEO of Esperion.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion’s Market Challenges: Sell Rating Due to Limited Impact of Bempedoic Acid and Mixed Feedback on Combination Strategy
- Esperion announces new data from CLEAR outcomes on NEXLETOL
- Promising Clinical Data and Strong Market Presence Drive Buy Rating for Esperion
- Esperion Therapeutics Reports Strong Q3 Revenue Growth
- Esperion Therapeutics Reports Strong Q3 Growth Amid Challenges